AGEN stock forecast, quote, news & analysis

Key Takeaways

• Agenus shares declined roughly 18% over the last 30 days, falling from about $7.85 to near $6.43, even as the stock remains sharply higher over the past quarter.
• The pullback followed a volatile late-September run-up that pushed the stock to a 52-week high near $10.31 before a wave of profit-taking set in during early October.
• Positive clinical updates — including 48% estimated three-year survival data for BOT+BAL in recurrent ovarian cancer — did not reverse the near-term selloff.
• The broader narrative remains defined by Agenus' strategic pivot to the Phase 3 ROBBIN trial in neoadjuvant MSS colon cancer and a $340 million financing completed in July.
• Investors are weighing high-beta biotech volatility, a clinical-stage cash-burn profile, and dilution risk against a large, underpenetrated commercial opportunity.

Agenus (AGEN) Company Overview and Market Position

Agenus Inc. is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts, and founded in 1994. Its lead program pairs botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody. The BOT+BAL combination is designed to activate both innate and adaptive immunity in "cold" tumors that have historically responded poorly to conventional checkpoint inhibitors.

The company's primary focus is microsatellite-stable (MSS) colorectal cancer, a setting representing the large majority of colon cancers. Agenus has treated more than 1,000 patients through late-line access programs and has generated survival data across multiple tumor types. Because it remains pre-commercial in major markets, the stock is closely followed for clinical data readouts, regulatory progress, financing decisions, and capital-efficiency signals rather than traditional earnings fundamentals.

Agenus (AGEN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AGEN declined approximately 18%, moving from a close of $7.85 in mid-September to roughly $6.43 by late October. The move was not linear: the stock climbed into late September, reaching an intraday 52-week high near $10.31, before a steep multi-week decline that erased most of those gains.

The picture over the last quarter is notably different. Measured from roughly $4.97 in mid-July, the stock is still up about 29% over the trailing three-month period. That contrast reflects the stock's elevated volatility — a sharp July surge, a second rally in late September, and a pronounced October pullback that leaves shares higher over the quarter but lower over the most recent month.

What Drove AGEN Stock Price in the Last 30 Days

The 30-day decline followed a momentum-driven advance. In late September, shares rallied from the mid-$8 range to a 52-week high near $10.31, extending the enthusiasm that followed the company's July strategic pivot. When a clinical-stage biotech runs up that quickly, mean-reversion and profit-taking can follow even in the absence of negative news.

Notably, the pullback occurred against a backdrop of constructive clinical updates. In early October, Agenus reported an estimated 48% three-year survival rate with BOT+BAL in the ovarian cancer cohort of its Phase 1b C-800-01 trial, presented at the 2026 International Gynecologic Cancer Society meeting — a meaningful result given that most treated patients had platinum-resistant disease. The company also announced upcoming BOT+BAL poster presentations at the SITC 2026 annual meeting, and confirmed its first marketing authorization for the combination, granted in Armenia for advanced MSS colorectal cancer.

Rather than reflecting a deterioration in the underlying story, the October selloff is best understood as high-beta biotech volatility: shares surged into data and conference catalysts, then gave back gains as momentum faded. Lingering concerns about a clinical-stage company's cash position and the dilutive structure of milestone-linked financing also weighed on sentiment, particularly after the sharp run-up inflated short-term valuations.

What Drove AGEN Stock Performance Over the Last Quarter

The quarterly trend is defined by a decisive strategic repositioning. In July 2026, Agenus discontinued its late-line BATMAN trial in refractory MSS metastatic colorectal cancer and shifted resources to ROBBIN, a global Phase 3 registrational study of neoadjuvant BOT+BAL in high-risk stage II and stage III MSS colon cancer. The company framed the earlier, curative-intent setting as its largest value opportunity, citing a U.S. addressable market it estimates at roughly $7 billion annually.

Alongside the pivot, Agenus announced a private placement of up to $340 million led by Commodore Capital with participation from RA Capital Management, TCGX, Invus and Ligand Pharmaceuticals. The financing included an $85 million upfront tranche and milestone-based warrant tranches tied to ROBBIN enrollment — including a potential $85 million tranche triggered at the 60th enrolled patient. That announcement roughly doubled the share price in a single session and remains the dominant driver of the stock's quarterly gain.

Supporting the repositioning, updated data from the NEST and UNICORN neoadjuvant studies showed deep pathologic responses and no observed recurrences with extended follow-up, reinforcing the rationale for the ROBBIN trial. The first marketing authorization in Armenia, while limited in commercial scope, provided an early regulatory validation point.

Trending AI Robots

For traders looking to complement their own analysis with systematic strategies, Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader universe of hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots appear in this section, each varying by strategy, timeframe, and performance metrics. The page is designed to help users identify currently favored automated approaches without making performance guarantees. Exploring the curated list can offer a useful starting point for those interested in data-driven, rules-based trading signals.

AGEN Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, the most important catalyst remains execution on the ROBBIN trial. Agenus has guided to first patient enrollment in the first quarter of 2027, with enrollment of the 60th patient — which would trigger a warrant tranche worth up to $85 million in potential proceeds — expected in the second quarter of 2027. An interim pathologic response readout on the first 100 patients is targeted for late 2027, followed by interim event-free survival analysis in the second half of 2029 and final analysis in the second half of 2030.

In the nearer term, investors should monitor data presentations such as the SITC 2026 posters in November and any updates to the UNICORN dataset, along with disclosures on cash runway, early-access program revenue, and the pace of global site activation for ROBBIN. Regulatory engagement, competitive developments in the MSS colon cancer space, and the company's capital position will also shape sentiment. As with all clinical-stage biotech investments, trial outcomes, financing terms, and broader market conditions carry meaningful risk, and this article is not intended as investment advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations